Report cover image

Global Neurodegenerative Disease Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 202 Pages
SKU # APRC20556102

Description

Summary

According to APO Research, the global Neurodegenerative Disease market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Neurodegenerative Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Neurodegenerative Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Neurodegenerative Disease market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Neurodegenerative Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Neurodegenerative Disease market include Biogen Idec, Boehringer Ingelheim, Merck Serono, UCB, BORA PHARMACEUTICALS, Dongcheng Biochemicals, Ark Pharmaceutical, GlaxoSmithKline and Haisco Pharmaceutical, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Neurodegenerative Disease, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Neurodegenerative Disease, also provides the value of main regions and countries. Of the upcoming market potential for Neurodegenerative Disease, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neurodegenerative Disease revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Neurodegenerative Disease market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Neurodegenerative Disease company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Neurodegenerative Disease Segment by Company

Biogen Idec
Boehringer Ingelheim
Merck Serono
UCB
BORA PHARMACEUTICALS
Dongcheng Biochemicals
Ark Pharmaceutical
GlaxoSmithKline
Haisco Pharmaceutical
Hisun Pharmaceutical
Huahai Pharmaceutical
Pfizer
Jingxin Pharmaceutical
Kanghong Pharmaceutical
Livzon Pharmaceutical
Luye Pharma
Novartis
Sanofi
TEVA
Neurodegenerative Disease Segment by Type

NMDA
SSRIs
Dopamine Inhibitors
Neurodegenerative Disease Segment by Application

Alzheimer’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Parkinson’s Disease
Neurodegenerative Disease Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Neurodegenerative Disease status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Neurodegenerative Disease key companies, revenue, market share, and recent developments.
3. To split the Neurodegenerative Disease breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Neurodegenerative Disease market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Neurodegenerative Disease significant trends, drivers, influence factors in global and regions.
6. To analyze Neurodegenerative Disease competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neurodegenerative Disease industry.
Chapter 3: Detailed analysis of Neurodegenerative Disease company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Neurodegenerative Disease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Neurodegenerative Disease in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

202 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Neurodegenerative Disease Market Size, 2020 VS 2024 VS 2031
1.3 Global Neurodegenerative Disease Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Neurodegenerative Disease Market Dynamics
2.1 Neurodegenerative Disease Industry Trends
2.2 Neurodegenerative Disease Industry Drivers
2.3 Neurodegenerative Disease Industry Opportunities and Challenges
2.4 Neurodegenerative Disease Industry Restraints
3 Neurodegenerative Disease Market by Company
3.1 Global Neurodegenerative Disease Company Revenue Ranking in 2024
3.2 Global Neurodegenerative Disease Revenue by Company (2020-2025)
3.3 Global Neurodegenerative Disease Company Ranking (2023-2025)
3.4 Global Neurodegenerative Disease Company Manufacturing Base and Headquarters
3.5 Global Neurodegenerative Disease Company Product Type and Application
3.6 Global Neurodegenerative Disease Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Neurodegenerative Disease Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Neurodegenerative Disease Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Neurodegenerative Disease Market by Type
4.1 Neurodegenerative Disease Type Introduction
4.1.1 NMDA
4.1.2 SSRIs
4.1.3 Dopamine Inhibitors
4.2 Global Neurodegenerative Disease Sales Value by Type
4.2.1 Global Neurodegenerative Disease Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Neurodegenerative Disease Sales Value by Type (2020-2031)
4.2.3 Global Neurodegenerative Disease Sales Value Share by Type (2020-2031)
5 Neurodegenerative Disease Market by Application
5.1 Neurodegenerative Disease Application Introduction
5.1.1 Alzheimer’s Disease
5.1.2 Huntington Disease
5.1.3 Amyotrophic Lateral Sclerosis
5.1.4 Parkinson’s Disease
5.2 Global Neurodegenerative Disease Sales Value by Application
5.2.1 Global Neurodegenerative Disease Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Neurodegenerative Disease Sales Value by Application (2020-2031)
5.2.3 Global Neurodegenerative Disease Sales Value Share by Application (2020-2031)
6 Neurodegenerative Disease Regional Value Analysis
6.1 Global Neurodegenerative Disease Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Neurodegenerative Disease Sales Value by Region (2020-2031)
6.2.1 Global Neurodegenerative Disease Sales Value by Region: 2020-2025
6.2.2 Global Neurodegenerative Disease Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Neurodegenerative Disease Sales Value (2020-2031)
6.3.2 North America Neurodegenerative Disease Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Neurodegenerative Disease Sales Value (2020-2031)
6.4.2 Europe Neurodegenerative Disease Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Neurodegenerative Disease Sales Value (2020-2031)
6.5.2 Asia-Pacific Neurodegenerative Disease Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Neurodegenerative Disease Sales Value (2020-2031)
6.6.2 South America Neurodegenerative Disease Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Neurodegenerative Disease Sales Value (2020-2031)
6.7.2 Middle East & Africa Neurodegenerative Disease Sales Value Share by Country, 2024 VS 2031
7 Neurodegenerative Disease Country-level Value Analysis
7.1 Global Neurodegenerative Disease Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Neurodegenerative Disease Sales Value by Country (2020-2031)
7.2.1 Global Neurodegenerative Disease Sales Value by Country (2020-2025)
7.2.2 Global Neurodegenerative Disease Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.3.2 USA Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.4.2 Canada Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.6.2 Germany Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.7.2 France Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.7.3 France Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.9.2 Italy Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.10.2 Spain Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.11.2 Russia Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.14.2 China Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.14.3 China Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.15.2 Japan Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.17.2 India Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.17.3 India Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.18.2 Australia Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.22.2 Chile Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.24.2 Peru Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.26.2 Israel Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.27.2 UAE Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.29.2 Iran Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Neurodegenerative Disease Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Neurodegenerative Disease Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Neurodegenerative Disease Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Biogen Idec
8.1.1 Biogen Idec Comapny Information
8.1.2 Biogen Idec Business Overview
8.1.3 Biogen Idec Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.1.4 Biogen Idec Neurodegenerative Disease Product Portfolio
8.1.5 Biogen Idec Recent Developments
8.2 Boehringer Ingelheim
8.2.1 Boehringer Ingelheim Comapny Information
8.2.2 Boehringer Ingelheim Business Overview
8.2.3 Boehringer Ingelheim Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.2.4 Boehringer Ingelheim Neurodegenerative Disease Product Portfolio
8.2.5 Boehringer Ingelheim Recent Developments
8.3 Merck Serono
8.3.1 Merck Serono Comapny Information
8.3.2 Merck Serono Business Overview
8.3.3 Merck Serono Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.3.4 Merck Serono Neurodegenerative Disease Product Portfolio
8.3.5 Merck Serono Recent Developments
8.4 UCB
8.4.1 UCB Comapny Information
8.4.2 UCB Business Overview
8.4.3 UCB Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.4.4 UCB Neurodegenerative Disease Product Portfolio
8.4.5 UCB Recent Developments
8.5 BORA PHARMACEUTICALS
8.5.1 BORA PHARMACEUTICALS Comapny Information
8.5.2 BORA PHARMACEUTICALS Business Overview
8.5.3 BORA PHARMACEUTICALS Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.5.4 BORA PHARMACEUTICALS Neurodegenerative Disease Product Portfolio
8.5.5 BORA PHARMACEUTICALS Recent Developments
8.6 Dongcheng Biochemicals
8.6.1 Dongcheng Biochemicals Comapny Information
8.6.2 Dongcheng Biochemicals Business Overview
8.6.3 Dongcheng Biochemicals Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.6.4 Dongcheng Biochemicals Neurodegenerative Disease Product Portfolio
8.6.5 Dongcheng Biochemicals Recent Developments
8.7 Ark Pharmaceutical
8.7.1 Ark Pharmaceutical Comapny Information
8.7.2 Ark Pharmaceutical Business Overview
8.7.3 Ark Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.7.4 Ark Pharmaceutical Neurodegenerative Disease Product Portfolio
8.7.5 Ark Pharmaceutical Recent Developments
8.8 GlaxoSmithKline
8.8.1 GlaxoSmithKline Comapny Information
8.8.2 GlaxoSmithKline Business Overview
8.8.3 GlaxoSmithKline Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.8.4 GlaxoSmithKline Neurodegenerative Disease Product Portfolio
8.8.5 GlaxoSmithKline Recent Developments
8.9 Haisco Pharmaceutical
8.9.1 Haisco Pharmaceutical Comapny Information
8.9.2 Haisco Pharmaceutical Business Overview
8.9.3 Haisco Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.9.4 Haisco Pharmaceutical Neurodegenerative Disease Product Portfolio
8.9.5 Haisco Pharmaceutical Recent Developments
8.10 Hisun Pharmaceutical
8.10.1 Hisun Pharmaceutical Comapny Information
8.10.2 Hisun Pharmaceutical Business Overview
8.10.3 Hisun Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.10.4 Hisun Pharmaceutical Neurodegenerative Disease Product Portfolio
8.10.5 Hisun Pharmaceutical Recent Developments
8.11 Huahai Pharmaceutical
8.11.1 Huahai Pharmaceutical Comapny Information
8.11.2 Huahai Pharmaceutical Business Overview
8.11.3 Huahai Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.11.4 Huahai Pharmaceutical Neurodegenerative Disease Product Portfolio
8.11.5 Huahai Pharmaceutical Recent Developments
8.12 Pfizer
8.12.1 Pfizer Comapny Information
8.12.2 Pfizer Business Overview
8.12.3 Pfizer Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.12.4 Pfizer Neurodegenerative Disease Product Portfolio
8.12.5 Pfizer Recent Developments
8.13 Jingxin Pharmaceutical
8.13.1 Jingxin Pharmaceutical Comapny Information
8.13.2 Jingxin Pharmaceutical Business Overview
8.13.3 Jingxin Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.13.4 Jingxin Pharmaceutical Neurodegenerative Disease Product Portfolio
8.13.5 Jingxin Pharmaceutical Recent Developments
8.14 Kanghong Pharmaceutical
8.14.1 Kanghong Pharmaceutical Comapny Information
8.14.2 Kanghong Pharmaceutical Business Overview
8.14.3 Kanghong Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.14.4 Kanghong Pharmaceutical Neurodegenerative Disease Product Portfolio
8.14.5 Kanghong Pharmaceutical Recent Developments
8.15 Livzon Pharmaceutical
8.15.1 Livzon Pharmaceutical Comapny Information
8.15.2 Livzon Pharmaceutical Business Overview
8.15.3 Livzon Pharmaceutical Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.15.4 Livzon Pharmaceutical Neurodegenerative Disease Product Portfolio
8.15.5 Livzon Pharmaceutical Recent Developments
8.16 Luye Pharma
8.16.1 Luye Pharma Comapny Information
8.16.2 Luye Pharma Business Overview
8.16.3 Luye Pharma Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.16.4 Luye Pharma Neurodegenerative Disease Product Portfolio
8.16.5 Luye Pharma Recent Developments
8.17 Novartis
8.17.1 Novartis Comapny Information
8.17.2 Novartis Business Overview
8.17.3 Novartis Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.17.4 Novartis Neurodegenerative Disease Product Portfolio
8.17.5 Novartis Recent Developments
8.18 Sanofi
8.18.1 Sanofi Comapny Information
8.18.2 Sanofi Business Overview
8.18.3 Sanofi Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.18.4 Sanofi Neurodegenerative Disease Product Portfolio
8.18.5 Sanofi Recent Developments
8.19 TEVA
8.19.1 TEVA Comapny Information
8.19.2 TEVA Business Overview
8.19.3 TEVA Neurodegenerative Disease Revenue and Gross Margin (2020-2025)
8.19.4 TEVA Neurodegenerative Disease Product Portfolio
8.19.5 TEVA Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.